We deliver wound therapies for superior outcomes. AediCell provides safe, effective, and easy to use products at a lower overall cost. Aedicell® is a regenerative medicine company that has developed a unique proprietary process to transform human tissue into biologics for therapy, focusing on the conversion of human placenta into two skin substitute products, Plurivest® and Dermavest®. The company’s mission is to deliver wound therapies for superior outcomes at a lower cost to the healthcare system by using rapid, advanced product development and manufacturing techniques. Aedicell was founded by Ted Burke who has spent his career in the manufacturing and biotechnology industries. A former manager at General Electric and director of manufacturing at Celgene Cellular Therapeutics, Ted is a Six Sigma Black Belt and skilled in process improvement and product development.
Aedicell® products have been designed to meet the needs of providers and patients.
- Manufactured at tissue bank with 25 years experience
- Every lot tested for biocompatibility
- FDA inspected
- Normal, healthy full term pregnancies
- 4 to 5X the tissue per cm
- Exposed surface area enables cell migration
- More growth factors
- Three year room temperature shelf life
- Shelf stable particulate pressed into contiguous sheet
- Spreads to cover over two times its listed size
- Can be molded to fit deep and tunneled wounds
- Maintains contact with the wound bed and does not float off
Savings of up to 50 percent
The only product on the market that combines human tissue sourced from the amniotic/chorionic membrane, umbilical cord AND placental disc —Dermavest®.
This combination delivers a myriad of cell attachment proteins (CAP) including collagen, proteoglycans, polysaccharides and cytokine/growth factors (GF’s) that, combined with the structural aspects of the placental connective tissue matrix, act as a scaffold for cell infiltration and proliferation.
Supplementing amnion and chorion with umbilical cord and placental disc tissue drives a novel therapeutic response in the varied In Vivo environments to which Dermavest is applied.
Placental tissue has been used for reconstructive and surgical applications since the early 1900s. In recent years, application of amniotic membranes has expanded to the treatment of chronic ulcers and soft tissue applications.
Placental tissue products have been shown to elicit a markedly different profile of proteins than other classes of skin substitutes including porcine intestinal submucosa, cadaver skin and collagen based wound coverings.
The attachment protein and cytokine/growth factor profile of Dermavest and Plurivest are unlike anything that is being offered in the market today. In Vitro studies demonstrate that Dermavest and Plurivest support the proliferation of Type-1 Collagen, Fibroblasts and Mesenchymal Stem cells.